HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
BIOBOARD - JERUSALEM
New compound for slowing the aging process can lead to novel treatments for brain diseases

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, has released new data showing that when combining two of its proprietary assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition's two-assay test can detect more than 50% of precancerous polyps.

Earlier this month, VolitionRx presented preliminary data from a 90 patient independent trial, later confirmed in a further 113 patients, at University Hospital Bonn in Germany. This data demonstrated 75% detection rates at 70% specificity when using a single assay. The Belgian team confirmed these results using the same single assay, but when combining it with another nucleosome biomarker they achieved even better results. They have now analysed 39 patients' samples from the ongoing prospective trial which includes both healthy patients and patients with benign colon disorders.

"This increased detection rate confirms our original hypothesis that combining nucleosomes increases the accuracy of the test," comments Dr. Jake Micallef, Chief Scientific Officer of VolitionRx. "We hope to further increase the sensitivity and specificity by adding more biomarkers and developing a larger panel of nucleosome tests."

Current diagnostic screening practices for colorectal cancer vary globally, from inviting at-risk groups to submit fecal occult blood tests to offering regular investigative colonoscopies. Unfortunately studies show compliance rates of between 30-60% for fecal blood tests, likely due to the uncomfortable nature of the test. Meanwhile, a US study found that less than 40% of people who were offered a colonoscopy screening actually attended.

Encouragingly, uptake of diagnostic blood tests is much higher, with one study showing annual prostate cancer screening compliance at higher than 80%. When VolitionRx's blood test is made publically available, higher uptake could be very likely. Additionally, if the research team continue to identify at least 50% of polyps this could also have vast implications for diagnosing earlier-stage colorectal cancers.

Professor Hans Jorgen Nielsen, Professor of Surgical Oncology at Hvidovre Hospital in Denmark, recently expanded his prospective study evaluating VolitionRx's panel as a colorectal cancer screening tool. He comments, "The 85% detection rate seen in this latest research is on par with rates achieved by fecal occult blood tests. If we could improve screening compliance by offering the public a simple, less intrusive test that is just as accurate, we could detect even more colorectal cancer cases in the earlier stages and survival rates could drastically improve."

This test has the potential to become a global first choice diagnostic tool, replacing fecal occult blood tests and preventing unnecessary colonoscopies around the world. The company hopes to apply for CE mark early next year and FDA approval roughly a year later.

Colorectal cancer is the third most prevalent cancer and fourth most common cause of cancer death worldwide.

Source: PR newswire

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy